Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

This study is a 1:1:1 randomized, double-blinded, controlled phase Ⅳ clinical trial in a military command in Beijing. Healthy individuals aged between 18～34 years who had not received any influenza vaccine during recent three years will be enrolled and administrated one dose TIV. Safety data will be collected for whole study (Day 0 to Day 30).Blood samples will be collected for immunogenicity assessments before injection and 21 days after vaccination.

Inclusion criteria

• Healthy servicemen aged between 18-34 years ,who had not received any influenza vaccine during recent three years;
• Proven legal identity;
• Written informed consent;
• Complying with the requirement of the study protocol;

Exclusion criteria

• Pregnant, breast feeding women;
• History of allergy to any vaccine or vaccine ingredient;
• Receipt of any immunosuppressant within 6 month prior to study entry;
• Congenital malformation, developmental disorders, serious chronic diseases, autoimmune disease, immunodeficiency, serious cardiovascular disease, diabetes, Guillain-Barré syndrome, hypertension that cannot be stabilized by medication, liver or kidney disease, or malignant tumor;
• Acute disease or acute stage of chronic disease within 7 days prior to study entry;
• Axillaty temperature > 37.0 °C;
• Any other factor that in the opinion of the investigator suggesting the volunteer is unsuitable for this study;